Phase I Study of Selinexor, Ixazomib, and Low-dose Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma.
作者信息
Salcedo Meghan, Lendvai Nikoletta, Mastey Donna, Schlossman Julia, Hultcrantz Malin, Korde Neha, Mailankody Sham, Lesokhin Alexander, Hassoun Hani, Smith Eric, Shah Urvi, Diab Victoria, Werner Kelly, Landau Heather, Lahoud Oscar, Drullinsky Pamela, Shah Gunjan, Chung David, Scordo Michael, Giralt Sergio, Landgren Ola
机构信息
Myeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY.
Adult Bone Marrow Transplant Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY.
出版信息
Clin Lymphoma Myeloma Leuk. 2020 Mar;20(3):198-200. doi: 10.1016/j.clml.2019.12.013. Epub 2019 Dec 26.
Abstract
摘要
相似文献
1
Phase I Study of Selinexor, Ixazomib, and Low-dose Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma.塞利尼索、伊沙佐米和低剂量地塞米松用于复发或难治性多发性骨髓瘤患者的I期研究。
Clin Lymphoma Myeloma Leuk. 2020 Mar;20(3):198-200. doi: 10.1016/j.clml.2019.12.013. Epub 2019 Dec 26.
2
Selinexor, Bortezomib, and Dexamethasone for Heavily Pretreated Multiple Myeloma: A Case Series.塞利尼索、硼替佐米和地塞米松用于多次预处理的多发性骨髓瘤：病例系列
Clin Lymphoma Myeloma Leuk. 2020 Dec;20(12):e947-e955. doi: 10.1016/j.clml.2020.07.016. Epub 2020 Jul 29.
3
Survival benefit of ixazomib, lenalidomide and dexamethasone (IRD) over lenalidomide and dexamethasone (Rd) in relapsed and refractory multiple myeloma patients in routine clinical practice.在常规临床实践中，来那度胺和地塞米松（Rd）与伊沙佐米、来那度胺和地塞米松（IRD）相比，对复发和难治性多发性骨髓瘤患者的生存获益。
BMC Cancer. 2021 Jan 15;21(1):73. doi: 10.1186/s12885-020-07732-1.
4
Selinexor, bortezomib, and dexamethasone (SVD) in heavily treated relapsed refractory multiple myeloma.塞利尼索、硼替佐米与地塞米松（SVD方案）用于多次治疗后的复发难治性多发性骨髓瘤
Ann Hematol. 2021 Dec;100(12):3057-3060. doi: 10.1007/s00277-020-04293-y. Epub 2020 Oct 2.
5
Randomized, double-blind, placebo-controlled phase III study of ixazomib plus lenalidomide-dexamethasone in patients with relapsed/refractory multiple myeloma: China Continuation study.随机、双盲、安慰剂对照的 III 期研究，评估伊沙佐米联合来那度胺-地塞米松治疗复发/难治性多发性骨髓瘤患者：中国延续研究。
J Hematol Oncol. 2017 Jul 6;10(1):137. doi: 10.1186/s13045-017-0501-4.
6
A phase II trial of continuous ixazomib, thalidomide and dexamethasone for relapsed and/or refractory multiple myeloma: the Australasian Myeloma Research Consortium (AMaRC) 16-02 trial.一项关于伊沙佐米、沙利度胺和地塞米松连续治疗复发和/或难治性多发性骨髓瘤的 II 期临床试验：澳大利亚骨髓瘤研究联盟（AMaRC）16-02 试验。
Br J Haematol. 2021 Aug;194(3):580-586. doi: 10.1111/bjh.17504. Epub 2021 May 15.
7
Ixazomib, lenalidomide, and dexamethasone combination in "real-world" clinical practice in patients with relapsed/refractory multiple myeloma.伊沙佐米、来那度胺和地塞米松联合用药用于复发/难治性多发性骨髓瘤患者的“真实世界”临床实践
Ann Hematol. 2022 Jan;101(1):81-89. doi: 10.1007/s00277-021-04663-0. Epub 2021 Sep 22.
8
[Analysis of the efficacy and survival of ixazomib-containing regimens in patients with refractory and relapsed multiple myeloma].含伊沙佐米方案治疗难治性和复发性多发性骨髓瘤患者的疗效及生存分析
Zhonghua Xue Ye Xue Za Zhi. 2022 Aug 14;43(8):680-684. doi: 10.3760/cma.j.issn.0253-2727.2022.08.011.
9
Healthcare resource utilization with ixazomib or placebo plus lenalidomide-dexamethasone in the randomized, double-blind, phase 3 TOURMALINE-MM1 study in relapsed/refractory multiple myeloma.在复发/难治性多发性骨髓瘤的随机、双盲、3期TOURMALINE-MM1研究中，使用伊沙佐米或安慰剂联合来那度胺-地塞米松的医疗资源利用情况。
J Med Econ. 2018 Aug;21(8):793-798. doi: 10.1080/13696998.2018.1474745. Epub 2018 May 29.
10
Ixazomib in the management of relapsed multiple myeloma.伊沙佐米在复发性多发性骨髓瘤中的治疗作用。
Future Oncol. 2018 Aug;14(20):2013-2020. doi: 10.2217/fon-2017-0710. Epub 2018 Feb 22.
引用本文的文献
1
Lowering the Selinexor Dose within the Pomalidomide and Dexamethasone Combination Regimen Elicits Fewer Side Effects While Comparable Efficacy Against Relapsed/Refractory Multiple Myeloma.在泊马度胺和地塞米松联合方案中降低塞利尼索剂量可减少副作用，同时对复发/难治性多发性骨髓瘤具有相当的疗效。
Onco Targets Ther. 2025 Jun 6;18:695-703. doi: 10.2147/OTT.S516486. eCollection 2025.
2
Treatment of multiple myeloma with selinexor: a review.塞利尼索治疗多发性骨髓瘤的综述
Ther Adv Hematol. 2024 Jan 5;15:20406207231219442. doi: 10.1177/20406207231219442. eCollection 2024.
3
Selinexor: Targeting a novel pathway in multiple myeloma.塞利尼索：靶向多发性骨髓瘤的一条新途径。
EJHaem. 2023 May 15;4(3):792-810. doi: 10.1002/jha2.709. eCollection 2023 Aug.
4
The Role of Belantamab Mafodotin, Selinexor, and Melflufen in Multiple Myeloma.贝兰他单抗马妥昔单抗、塞利尼索和来那度胺在多发性骨髓瘤中的作用。
Curr Hematol Malig Rep. 2022 Dec;17(6):306-318. doi: 10.1007/s11899-022-00682-4. Epub 2022 Nov 22.
5
Efficacy and safety of selinexor-based regimens for relapsed/refractory multiple myeloma: a systematic review of literature.基于塞利尼索的方案治疗复发/难治性多发性骨髓瘤的疗效和安全性：文献系统评价
Ann Hematol. 2022 Dec;101(12):2601-2610. doi: 10.1007/s00277-022-04999-1. Epub 2022 Oct 10.
6
Ixazomib with cyclophosphamide and dexamethasone in relapsed or refractory myeloma: MUKeight phase II randomised controlled trial results.来那度胺联合环磷酰胺和地塞米松治疗复发或难治性多发性骨髓瘤：MUKeight 期随机对照试验结果。
Blood Cancer J. 2022 Apr 1;12(4):52. doi: 10.1038/s41408-022-00626-4.
7
Safety and Efficacy Analysis of Selinexor-Based Treatment in Multiple Myeloma, a Meta-Analysis Based on Prospective Clinical Trials.基于前瞻性临床试验的多发性骨髓瘤塞利尼索治疗安全性和疗效分析：一项荟萃分析
Front Pharmacol. 2021 Dec 3;12:758992. doi: 10.3389/fphar.2021.758992. eCollection 2021.
8
Novel Approaches Outside the Setting of Immunotherapy for the Treatment of Multiple Myeloma: The Case of Melflufen, Venetoclax, and Selinexor.多发性骨髓瘤治疗中免疫治疗之外的新型方法：美法仑氟芬、维奈克拉和塞利尼索的案例
Front Oncol. 2021 Sep 30;11:716751. doi: 10.3389/fonc.2021.716751. eCollection 2021.
9
Clinical Utility of Selinexor/Dexamethasone in Patients with Relapsed or Refractory Multiple Myeloma: A Review of Current Evidence and Patient Selection.塞利尼索/地塞米松在复发或难治性多发性骨髓瘤患者中的临床应用：当前证据及患者选择综述
Onco Targets Ther. 2020 Jul 1;13:6405-6416. doi: 10.2147/OTT.S227166. eCollection 2020.
本文引用的文献
1
Phase 1 study of selinexor plus carfilzomib and dexamethasone for the treatment of relapsed/refractory multiple myeloma.Selinexor 联合卡非佐米和地塞米松治疗复发/难治性多发性骨髓瘤的 1 期研究。
Br J Haematol. 2019 Aug;186(4):549-560. doi: 10.1111/bjh.15969. Epub 2019 May 24.
2
Selinexor plus low-dose bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma.塞利尼索联合低剂量硼替佐米和地塞米松治疗复发/难治性多发性骨髓瘤患者。
Blood. 2018 Dec 13;132(24):2546-2554. doi: 10.1182/blood-2018-06-858852. Epub 2018 Oct 23.
3
Selective Inhibition of Nuclear Export With Oral Selinexor for Treatment of Relapsed or Refractory Multiple Myeloma.口服 Selinexor 选择性抑制核输出治疗复发/难治性多发性骨髓瘤。
J Clin Oncol. 2018 Mar 20;36(9):859-866. doi: 10.1200/JCO.2017.75.5207. Epub 2018 Jan 30.
Zotero 插件